NEW YORK – With COVID-19 vaccinations beginning this week in the US, the country is entering a new stage of the pandemic that could ultimately end in widespread suppression of the virus.
The implications of this development for the lab industry are not entirely clear, but after almost a year spent building out molecular capacities to meet SARS-CoV-2 test demand, the question of what to do with that capacity in a post-COVID-19 environment looms on the horizon.